Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
published in: Lancet Oncology Commission
date of publication: 2012-02-21
main subject: lymphocyte, leukemia
Cites articles 26
- 2006-01-01
Date
Title
Article - wd:Q40295439